



Atty. Docket No.: 8822/2022

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bachmann, et al.
Serial No.: 10/762,107
Filed: January 21, 2004
Entitled: Farnesyl Dibenzodiazepinone, Process
for Its Production and its Use as a
Pharmaceutical

Examiner: Not yet assigned

Group Art Unit: 1624

Conf. No.: 4987

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary Wilson

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 8822/2022. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: 2/16/05

Name: Mark J. FitzGerald

Registration No.: 45,928

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.: 8822/2022 PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bachmann, et al.
Serial No.: 10/762,107
Filed: January 21, 2004
Entitled: Farnesyl Dibenzodiazepinone, Process
for Its Production and its Use as a
Pharmaceutical

Examiner: Not yet assigned
Group Art Unit: 1624
Conf. No.: 4987

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary Wilson

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Supplemental Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents, as well as, for the Examiner's convenience, copies of all foreign patent documents and non-patent literature are enclosed. This application was filed after June 30, 2003, and copies of U.S. patents and U.S. patent applications are not required and are not enclosed.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date:

2/16/05

Respectfully submitted,

Mark J. FitzGerald

Name: Mark J. FitzGerald

Registration No.: 45,928

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100


U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

8822/2022

Serial No.

10/762,107

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

Applicant(s): Bachmann, et al.

Filing Date: January 21, 2004

Group: 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	1.	4,452,775	June 5, 1984	Kent	424	425	
	2.	5,039,660	August 13, 1991	Leonard, et al.	514	8	
	3.	5,830,695	November 3, 1998	Serizawa, et al.	435	69.1	
	4.	5,466,590	November 14, 1995	Sariaslani, et al.	435	189	
	5.	5,556,772	September 17, 1996	Sorge, et al.	435	91.2	
	6.	5,523,288	June 4, 1996	Cohen, et al.	514	12	
	7.	5,783,561	July 21, 1998	Horwitz, et al.	514	12	
	8.	6,140,306	October 31, 2000	Lambert, Jr., et al.	514	12	
	9.	5,393,665	February 28, 1995	Fayerman, et al.	435	486	
	10.	3,854,480	December 17, 1974	Zaffaroni	128	260	
	11.	10/232,370	September 3, 2002	Ecopia Biosciences, Inc.	C12Q	1/68	
	12.	09/953,403	September 17, 2001	Science & Engineering Serv.	H01J	49/04	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	13.	Berge, et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences (1977), V. 66, No. 1, Pages 1-19.
	14.	Goodfellow, "Suprageneric Classification of Actinomycetes", Bergey's Manual of Systematic Bacteriology (1989), V. 4, Pages 2333-2339.
	15.	Embley and Stackebrandt, "The Molecular Phylogeny and Systematics of the Actinomycetes", Annu. Rev. Microbiol. (1994), V. 48, Pages 257-289.
	16.	Zazopoulos, et al., "A Genomics-Guided Approach for Discovering and Expressing Cryptic Metabolic Pathways", Nature Biotechnology (2003), V. 21, Pages 187-190.
	17.	Stryer, :Biochemistry 3 rd Edition (1998), W.H. Freeman and Co., New York, Pages 752-754.
	18.	Altschul, et al., "Basic Local Alignment Search Tool", Journal of Molecular Biology (1990), V. 215, No. 3, Pages 403-410.

19.	Takagi, et al., "A Gene Cluster for the Mevalonate Pathway from <i>Streptomyces</i> sp. Strain CL190", <i>Journal of Bacteriology</i> (2000), V. 182, No. 15, Pages 4153-4157.
20.	Carrillo, et al., "The Multiple Sequence Alignment Problem in Biology", <i>Applied Math</i> (1998), V. 48, No. 5, Pages 1073-1082.
21.	Murakami, et al., "Thiostrepton-Induced Gene Expression in <i>Streptomyces Lividans</i> ", <i>Journal of Bacteriology</i> (1989), V. 171, No. 3, Pages 1459-1466.
22.	Thompson, et al., "Cloning of Antibiotic Resistance and Nutritional Genes in Streptomycetes", <i>Journal of Bacteriology</i> (1982), V. 151, No. 2, Pages 668-677.
23.	Hopwood, et al., "Plasmid and Phage Vectors for Gene Cloning and Analysis in <i>Streptomyces</i> ", <i>Methods in Enzymology</i> (1987), V. 153, Pages 116-166.
24.	Nielson, et al., "Taq Extender PCR Additive for Improved Length, Yield, and Reliability of PCR Products", <i>Strategies</i> (1994), V. 7, Page 27.
25.	Matteucci, et al., "Synthesis of Deoxyoligonucleotides on a Polymer Support", <i>American Chemical Society</i> (1981), V. 103, No. 11, Pages 3185-3191.
26.	Gluzman, et al., "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants", <i>Cell</i> (1981), V. 23, No. 1, Pages 175-182.
27.	Vaara, "Agents that Increase the Permeability of the Outer Membrane", <i>Microbiological Reviews</i> (1992), V. 56, No. 3, Pages 395-411.
28.	Tsubery, et al., "Structure-Function Studies of Polymyxin B Nonapeptide: Implications to Sensitization of Gram-Negative Bacteria", <i>Journal of Medical Chemistry</i> (2000), V. 43, No. 16, Pages 3085-3092.
29.	Carter, et al., "5-Lipoxygenase Inhibitory Activity of Zileuton", <i>Journal of Pharmacology and Experimental Therapeutics</i> (1991), V. 256, No. 3, Pages 929-937.
30.	Safayhi, et al., "Concentration-Dependent Potentiating and Inhibitory Effects of Boswellia Extracts on 5-Lipoxygenase Product Formation in Stimulated PMNL", <i>Planta Medica</i> (2000), V. 66, No. 2, Pages 110-113.
31.	Workman, P., "UKCCR Guidelines for the Welfare of Animals in Experimental Neoplasia", <i>United Kingdom Coordinated Committee on Cancer Research, British Journal of Cancer 2nd Edition</i> (1997), V. 77, Pages 1-10.
32.	Premont, et al., "[³ H] Norepinephrine Binding by Rat Glial Cells in Culture. Lack of Correlation between Binding and Adenylate Cyclase Activation", <i>Biochimica et Biophysica Acta</i> (1975), V. 381, No. 2, Pages 368-376.
33.	Dimitradou, et al., "Identification and Characterization of a New Cytotoxic Agent from Actinomycetes", <i>Poster Presentation Presented at the AACR Annual Meeting, Orlando, FL, March 27 to 31 2004.</i>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.